ReviewBiomedical engineering online2025
Applications of recombinant type III collagen in tissue engineering.
Review in Biomedical engineering online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Injectable Hydroxyapatite-Reinforced Methacrylated Recombinant Type III Collagen Microgels for Soft-Tissue Filling.Gels (Basel, Switzerland) · 2026Article
- Treatment of interstitial cystitis with intravesical instillation of recombinant human collagen type Ⅲ.The Canadian journal of urology · 2026Article
- Activating the cellular scavenger: A bioactive hydrogel promotes diabetic wounds via plant exosome-like nanovesicles enhanced macrophage efferocytosis.Bioactive materials · 2026Article
- High-level secretory production of a highly hydrophilic human-like type III collagen in Komagataella phaffii by a multicopy genomic integration strategy.Biotechnology letters · 2026Article
- A recombinant humanized type III collagen coating with anti-inflammatory and endothelialization-promoting effects for left atrial appendage closure devices.Regenerative biomaterials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recombinant human type III collagen (rhCol III) is a promising biomaterial for tissue engineering due to its excellent biocompatibility and bioactivity. This review summarizes the structure, development, and applications of rhCol III in bone and soft tissue engineering. Advances in genetic engineering have enabled the production of rhCol III with customizable properties. It plays a key role in promoting tissue repair and regeneration, with significant potential in wound healing, skin repair, and anti-inflammatory responses. However, challenges remain in optimizing its mechanical properties for specific applications. Future research should focus on improving production efficiency and clinical translation while addressing potential host responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.